These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37390404)

  • 1. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease.
    Flynn JM; Huang QYJ; Zvornicanin SN; Schneider-Nachum G; Shaqra AM; Yilmaz NK; Moquin SA; Dovala D; Schiffer CA; Bolon DNA
    ACS Infect Dis; 2023 Jul; 9(7):1372-1386. PubMed ID: 37390404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
    Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
    J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.
    Costacurta F; Dodaro A; Bante D; Schöppe H; Peng JY; Sprenger B; He X; Moghadasi SA; Egger LM; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Dunzendorfer-Matt T; Naschberger A; Wang D; Kaserer T; Moro S; von Laer D; Heilmann E
    PLoS Pathog; 2024 Sep; 20(9):e1012522. PubMed ID: 39259728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contributions of Hyperactive Mutations in M
    Flynn JM; Zvornicanin SN; Tsepal T; Shaqra AM; Kurt Yilmaz N; Jia W; Moquin S; Dovala D; Schiffer CA; Bolon DNA
    ACS Infect Dis; 2024 Apr; 10(4):1174-1184. PubMed ID: 38472113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.
    Duan Y; Zhou H; Liu X; Iketani S; Lin M; Zhang X; Bian Q; Wang H; Sun H; Hong SJ; Culbertson B; Mohri H; Luck MI; Zhu Y; Liu X; Lu Y; Yang X; Yang K; Sabo Y; Chavez A; Goff SP; Rao Z; Ho DD; Yang H
    Nature; 2023 Oct; 622(7982):376-382. PubMed ID: 37696289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and virologic mechanism of the emergence of resistance to M
    Hattori SI; Bulut H; Hayashi H; Kishimoto N; Takamune N; Hasegawa K; Furusawa Y; Yamayoshi S; Murayama K; Tamamura H; Li M; Wlodawer A; Kawaoka Y; Misumi S; Mitsuya H
    Proc Natl Acad Sci U S A; 2024 Sep; 121(37):e2404175121. PubMed ID: 39236245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.
    Colson P; Delerce J; Pontarotti P; Devaux C; La Scola B; Fantini J; Raoult D
    J Med Virol; 2024 Feb; 96(2):e29462. PubMed ID: 38363015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly specific SARS-CoV-2 main protease (M
    Rauch S; Costacurta F; Schöppe H; Peng JY; Bante D; Erisoez EE; Sprenger B; He X; Moghadasi SA; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Wang D; Naschberger A; Dunzendorfer-Matt T; Kaserer T; von Laer D; Heilmann E
    Antiviral Res; 2024 Nov; 231():105969. PubMed ID: 39053514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    bioRxiv; 2022 Aug; ():. PubMed ID: 36032976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    Nature; 2023 Jan; 613(7944):558-564. PubMed ID: 36351451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
    Zhou Y; Gammeltoft KA; Ryberg LA; Pham LV; Tjørnelund HD; Binderup A; Duarte Hernandez CR; Fernandez-Antunez C; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Sci Adv; 2022 Dec; 8(51):eadd7197. PubMed ID: 36542720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 3CL
    Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
    Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
    Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.
    Padhi AK; Tripathi T
    Biochem Biophys Res Commun; 2022 Nov; 629():54-60. PubMed ID: 36113178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.
    Zhu Y; Yurgelonis I; Noell S; Yang Q; Guan S; Li Z; Hao L; Rothan H; Rai DK; McMonagle P; Baniecki ML; Greasley SE; Plotnikova O; Lee J; Nicki JA; Ferre R; Byrnes LJ; Liu W; Craig TK; Steppan CM; Liberator P; Soares HD; Allerton CMN; Anderson AS; Cardin RD
    Sci Adv; 2024 Jul; 10(30):eadl4013. PubMed ID: 39047088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive study of SARS-CoV-2 main protease (M
    Costacurta F; Dodaro A; Bante D; Schöppe H; Sprenger B; Moghadasi SA; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Kaserer T; Moro S; von Laer D; Heilmann E
    bioRxiv; 2023 Oct; ():. PubMed ID: 37808638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
    Kiso M; Furusawa Y; Uraki R; Imai M; Yamayoshi S; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):3952. PubMed ID: 37402789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.